Gilead, Bristol-Myers Squibb Facing Antitrust Class Action Over Alleged Anti-Competitive Grip on HIV Drug Market
October 13, 2020 A class action alleges Gilead Sciences and Bristol-Myers Squibb have for years conspired to restrain the U.S. market for HIV treatment drugs, allowing the companies to overcharge direct buyers.